Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CYT006-AngQb: Phase IIa data

In a double-blind, placebo-controlled Phase IIa trial in 72 patients, CYT006-AngQb injections

Read the full 123 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE